Inactive Instrument

MDxHealth SA Stock Euronext Bruxelles

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

Sales 2024 * 78.66M 85.1M Sales 2025 * 89.78M 97.13M Capitalization 69.13M 74.79M
Net income 2024 * -26M -28.13M Net income 2025 * -17M -18.39M EV / Sales 2024 * 2.19 x
Net Debt 2024 * 103M 112M Net Debt 2025 * 121M 131M EV / Sales 2025 * 2.12 x
P/E ratio 2024 *
-2.72 x
P/E ratio 2025 *
-4.03 x
Employees 300
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.92%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 19-02-17
Director of Finance/CFO 50 19-07-21
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 74 21-09-28
Director/Board Member 52 20-07-29
Director/Board Member 59 17-10-31
More insiders
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Calendar
More about the company